Veeva Systems is a best-in-class life sciences software business with 28% net margins, 134% free cash flow conversion, and a four-quarter earnings beat streak, but a confirmed price downtrend with the 50-day moving average crossing below the 200-day moving average blocks near-term entry despite attractive analyst upside of 51%.
Thesis pillars
- Best In Class Margins Fcf→Stable
- Consistent Earnings Beat Record↓Deteriorating
- Death Cross Momentum Downtrend→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 20, 2026· older than 90 days
Veeva Systems Inc. (VEEV) Stock Analysis
Range Bound setup · Catalyst-Driven edge
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $310.63, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: North America; Analyst target reached - limited upside remaining.
Veeva provides cloud software, data, and consulting to the global life sciences industry through four product suites—Commercial, Data, Development, and Quality Cloud—serving 1,552 customers including major pharma and biotech companies as of January 31, 2026. Revenue comes from... Read more
Hold if already holding. Not a fresh buy at $310.63, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: North America; Analyst target reached - limited upside remaining. Chart setup: RSI 48 mid-range, Bollinger mid-band. Downgraded from BUY WAIT — price $310.63 vs the analyst target $273.17: -12.1% upside; No upside left. Score 6.2/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, earnings proximity 20d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Veeva Systems Inc.
About Veeva Systems Inc.
Veeva's cloud platform serves 1,552 life sciences customers as of January 31, 2026—spanning pharmaceutical, biotechnology, and medical device companies across the globe—with customers outside North America generating approximately 40% of total revenues. The company employed 7,928 people, up by 637 from the prior year, supporting four product suites: Commercial Cloud, Development Cloud, Quality Cloud, and Data Cloud.
Veeva generates revenue through subscriptions to cloud applications and professional services, organized into two reporting tracks—Commercial Solutions (Commercial Cloud and Data Cloud) and R&D and Quality Solutions (Development Cloud and Quality Cloud)—sold through a direct sales force aligned to pharmaceutical and biotechnology customers' separate commercial and R&D decision-making structures. The Commercial Cloud includes Vault CRM, the successor to Veeva CRM, which relies on the Salesforce platform and will be supported only through December 31, 2029. Data products—including Veeva OpenData, Compass, and Link—compete with IQVIA Holdings, Ipsos, and Definitive Health. The Development Cloud and Quality Cloud address clinical trial management, regulatory submissions, and quality management, competing with IQVIA, Dassault Systèmes, Oracle, and OpenText. Top-10 customers accounted for 28% of total revenues in each of the three fiscal years ended January 31, 2026, 2025, and 2024—stable concentration in a blue-chip customer base.
Show full overview
Veeva CRM relies on the Salesforce platform until December 31, 2029, and the migration to Vault CRM carries execution risk: Salesforce has announced that certain large Veeva CRM customers have committed to purchasing its CRM solutions, and Veeva acknowledges other customers may follow. If migration to Vault CRM encounters disruptions or delays, or if additional customers move to Salesforce, Commercial Cloud subscription revenue could be adversely affected across multiple renewal cycles. The 10-K also identifies cybersecurity threats as a material risk given the platform stores clinical trial data, regulatory submissions, and patient information.
See also: Healthcare · Health Information Services
From Veeva Systems Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Veeva Systems Inc.
Latest news
- NEWS VEEV Stock Price and Chart — NYSE:VEEV - TradingView — TradingView Nov 3, 2026 neutral
- NEWS Veeva Systems (VEEV): Turning Industry Expertise into Growth - Yahoo Finance — Yahoo Finance Nov 3, 2026 positive
- NEWS Veeva Systems (NYSE:VEEV) Stock Price Target Raised at Barclays - MarketBeat — MarketBeat Oct 28, 2026 positive
- NEWS Veeva Systems Inc. (VEEV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance — Yahoo Finance Oct 28, 2026 neutral
- NEWS Veeva Systems: Same Old Story, Same Rating Once Again - Seeking Alpha — Seeking Alpha Sep 30, 2026 neutral
Latest item Nov 3, 2026 · Generated 2026-11-05T11:34:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertop 10 customers28%10-K Item 1A: 'our top 10 customers accounted for 28% of our total revenues'
- HIGHGeographicNorth America10-K Item 1A: 'customers outside North America accounted for approximately 40% of our total revenues'
Material Events(8-K, last 90d)
- 2026-04-20Item 5.02MEDIUMJosh Faddis, SVP and General Counsel, intends to retire effective November 1, 2026, transitioning to a part-time advisor role. Veeva will appoint a successor upon his transition. No reason cited beyond retirement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $310.63, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: North America; Analyst target reached - limited upside remaining. Chart setup: RSI 48 mid-range, Bollinger mid-band. Downgraded from BUY WAIT — price $310.63 vs the analyst target $273.17: -12.1% upside; No upside left. Analyst target $273.17 reached (−12.1%), stop $270.65 (−14.8%), A.R:R -1.2:1. Score 6.2/10, moderate confidence.
Analyst target $273.17 reached (−12.1% from $310.63); no take-profit level is published. Analyst target $273.17 reached (−12.1%), stop $270.65 (−14.8%), A.R:R -1.2:1. Stop-loss: $270.65.
Concentration risk — Geographic: North America; Analyst target reached - limited upside remaining; Near 52-week high (4.7% away).
Veeva Systems Inc. trades at a P/E of 50.9 (forward 30.3). TrendMatrix value score: 3.0/10. Verdict: Hold.
35 analysts rate VEEV, with a consensus score of 4.0/5. 27 analysts publish price targets averaging $304.
What does Veeva Systems Inc. do?Veeva provides cloud software, data, and consulting to the global life sciences industry through four product...
Veeva provides cloud software, data, and consulting to the global life sciences industry through four product suites—Commercial, Data, Development, and Quality Cloud—serving 1,552 customers including major pharma and biotech companies as of January 31, 2026. Revenue comes from subscriptions and professional services, with 7,928 employees. The platform is deeply embedded in regulated workflows for clinical trials, regulatory submissions, CRM, and quality management.